PROTOCOL SYNOPSIS – BMT CTN PROTOCOL #1202

Prospective Multi-Center Cohort for the Evaluation of Biomarkers Predicting Risk of Complications and Mortality Following Allogeneic HCT

Study Chairpersons: John Levine, M.D. and John Hansen, M.D.

Objective: The goal of this protocol is to establish a cohort of biologic samples collected prospectively from patients treated in BMT CTN centers that will be a shared biospecimen resource for conducting future allogeneic hematopoietic stem cell transplantation (HCT) correlative studies.

Accrual Objective: A minimum of 1,500 patients will be enrolled.

Accrual Period: The estimated accrual period is 4 years.

Eligibility Criteria: All U.S. Allogeneic Transplant Donors and Recipients weighing 10 or more kg may participate in the collection of samples.

Treatment Plan: Conditioning regimens, GVHD prophylaxis, and other supportive care will follow institutional guidelines.

Study Duration: Patients will be followed for 24 months post-HCT; long-term follow-up data will be collected through usual procedures of the Center for International Blood and Marrow Transplant Research (CIBMTR).